当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
Glassia, Alpha-1-Proteinase Inhibitor (Human)
药品名称
Glassia, Alpha-1-Proteinase Inhibitor (Human)
承诺描述
Conduct a study investigating Epithelial Lining Fluid of Alpha1-Antitrypsin Deficient Patients for Alpha1-PI and analytes levels following augmentation therapy with GLASSIA. The primary endpoint for this study will be both antigenic and functional Alpha1-PI levels in Epithelial Lining Fluid after 10-12 weeks of treatment.
承诺状态描述
The study completion date has passed and the study has not yet been completed. The final report due date has passed with no final report received.